DarioHealth revenue slips 4% to $5.2 million
- DarioHealth reported Q2 2026 revenue of $5.2 million, down from $5.4 million a year earlier, while gross margin improved to 62%.
- Operating expenses fell 21% and net loss narrowed to $7.9 million, while DRIO shares rose about 3.1% to $7.90.
- DarioHealth reported $13.1 million of contracted and late-stage ARR as it shifts toward higher-margin recurring B2B2C business.
DarioHealth (NASDAQ:DRIO) reported second-quarter 2026 revenue of $5.2 million, down about 4% year over year, while gross margin improved to 61.7%.
Revenue declined from $5.4 million a year earlier and $5.6 million in Q1 as DarioHealth discontinued certain pharmaceutical-related business while expanding recurring B2B2C revenue.
Operating expenses fell 21% to $9.7 million, operating loss narrowed to $6.5 million and net loss improved to $7.9 million from $13.0 million.
Following the announcement, DarioHealth's share price was up about 3.1% at $7.90 in Nasdaq trading.
DarioHealth reported $13.1 million of contracted and late-stage ARR, with more than 80% tied to multi-condition offerings, alongside new health-plan and Fortune 50 wins.
The company raised $22.8 million net through a July financing, taking pro forma cash to $36.8 million as it expands through Solera, Amwell and provider-backed care.
Frequently asked questions
More from United States
Merck raises FY profit outlook as Q3 revenue climbs 5% to $18.1B
Eli Lilly Q3 revenue surges 39% to $24.4 billion as guidance rises
Enterprise Products Q3 EBITDA jumps 16% to $2.8 billion
KBR Q3 revenue rises 5% to $2 billion as adjusted EBITDA grows 12%
Enerflex Q3 free cash flow rises to $102 million as net earnings climb
WTW Q3 revenue rises 8% to $2.46 billion as AI savings plan advances
